ArticleJournal of Ayurveda and integrative medicine
Therapeutic effects of Ghrita Manda Ashchyotana on tear film stability, corneal integrity, and IL-6 expression in a benzalkonium chloride-induced murine dry eye model.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDry Eye (DE) is a condition marked by tear film instability and chronic inflammation, leading to visual impairment. Conventional artificial tears often contain preservatives that exacerbate DE and fail to address underlying tissue damage. In Ayurveda, DE symptoms corelates with Sushkakshipaka, managed by normalizing vata pitta derangement. This study evaluates the mechanism of Ghrita MandaAshchyotana in a Benzalkonium Chloride (BAC)-induced murine dry eye model. METHODOLOGY: 12 male Swiss albino mice (24 eyes) were divided into: saline-treated controls (3 mice), and dry eye-induced mice treated with either Ghrita Manda (Trial), preservative-free eye drops (Positive control), or left untreated (Negative control). Assessments included Tear Film Break-Up Time (TFBUT), fluorescein scores, corneal Hematoxylin and Eosin (H&E) staining, and IL-6 expression after 14 days.
resultsGhrita Manda significantly improved TFBUT and reduced fluorescein scores compared to the negative control (p < 0.001). Corneal integrity was preserved without hyperplasia in the trial group. A notable reduction in IL-6 expression was observed compared to the positive control.
conclusionGhrita Manda demonstrates potential as an effective DE therapy, offering lubrication, corneal protection, and anti-inflammatory benefits, aligning with Ayurvedic principles for managing vata pitta derangements of the ocular surface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.